Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 9/20 | 0.73 |
| ▸ | MAPT | P10636 | 4/20 | 0.67 |
| ▸ | RAB9A | P51151 | 4/20 | 0.67 |
| ▸ | NPC1 | O15118 | 4/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | AMY1A | P0DUB6 | 3/20 | 0.64 |
| ▸ | HTT | P42858 | 2/20 | 0.63 |
| ▸ | MMP2 | P08253 | 1/20 | 0.63 |
| ▸ | MMP9 | P14780 | 1/20 | 0.63 |
| ▸ | MMP8 | P22894 | 1/20 | 0.63 |
| ▸ | CASP3 | P42574 | 1/20 | 0.63 |
| ▸ | MMP13 | P45452 | 1/20 | 0.63 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.63 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.63 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.63 |
| ▸ | F2 | P00734 | 1/20 | 0.63 |
| ▸ | F10 | P00742 | 1/20 | 0.63 |
| ▸ | PLG | P00747 | 1/20 | 0.63 |
| ▸ | PLAU | P00749 | 1/20 | 0.63 |
| ▸ | PLAT | P00750 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30397301 | 1.00 | NPBWR1 (0.73) | NPBWR1MAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL2250346 | 0.91 | NPBWR1 (0.60) | NPBWR1MAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL17898275 | 0.90 | NPBWR1 (0.66) | NPBWR1MAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL4497816 | 0.88 | NPBWR1 (0.74) | NPBWR1MAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL17898254 | 0.87 | NPBWR1 (0.72) | NPBWR1MAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL4487886 | 0.86 | NPBWR1 (0.76) | NPBWR1MAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL7394839 | 0.86 | NPBWR1 (0.74) | NPBWR1MAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL17898269 | 0.86 | NPBWR1 (0.70) | NPBWR1MAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL28607204 | 0.85 | NPBWR1 (0.74) | NPBWR1MAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL3190714 | 0.84 | AMY1A (0.73) | NPBWR1MAPTRAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113698353-B | Imidazolyl Schiff base fluorescence sensor for detecting copper (II) particles in aqueous solution and synthesis method thereof | 桂林理工大学 | 2023-05-05 | — | — | CN | claimed |
| CN-113698353-A | Imidazolyl Schiff base fluorescence sensor for detecting copper (II) particles in aqueous solution and synthetic method thereof | 桂林理工大学 | 2021-11-26 | — | — | CN | claimed |
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | SUMMIT (OXFORD) LIMITED (GB) | 2011-08-11 | — | — | US | claimed |
| CN-113698353-B | Imidazolyl Schiff base fluorescence sensor for detecting copper (II) particles in aqueous solution and synthesis method thereof | 桂林理工大学 | 2023-05-05 | — | — | CN | disclosed |
| CN-113698353-A | Imidazolyl Schiff base fluorescence sensor for detecting copper (II) particles in aqueous solution and synthetic method thereof | 桂林理工大学 | 2021-11-26 | — | — | CN | disclosed |
| EP-3251694-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit (Oxford) Limited (GB) | 2017-12-06 | — | — | EP | disclosed |
| EP-1986633-B1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORP PLC (GB) | 2014-07-30 | — | — | EP | disclosed |
| US-20140018320-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2014-01-16 | — | — | US | disclosed |
| US-20140011782-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2014-01-09 | — | — | US | disclosed |
| US-8518980-B2 | Treatment of Duchenne muscular dystrophy | SUMMIT CORPORATION PLC (GB) | 2013-08-27 | — | — | US | disclosed |
| US-8501713-B2 | Drug combinations for the treatment of duchenne muscular dystrophy | SUMMIT CORPORATION PLC (GB) | 2013-08-06 | — | — | US | disclosed |
| EP-2170396-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | BioMarin IGA Limited (BS) | 2010-04-07 | — | — | EP | disclosed |
| CN-101678107-A | Pharmaceutical composition for treating Duchenne muscular dystrophy | SUMMIT CORP PLC | 2010-03-24 | — | — | CN | disclosed |
| CN-101420950-A | Treatment of Duchenne muscular dystrophy | SUMMIT CORP PLC (GB) | 2009-04-29 | — | — | CN | disclosed |
| US-20090075938-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT (OXFORD) LIMITED (GB) | 2009-03-19 | — | — | US | disclosed |
| WO-2009019504-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2009-02-12 | — | — | WO | disclosed |
| EP-1986633-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit Corporation Plc (GB) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007091106-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2007-08-16 | — | — | WO | disclosed |
| WO-2001066526-A1 | ESTER DERIVATIVES OF DIMETHYLPROPIONIC ACID AND PHARMACETUICAL COMPOSITIONS CONTAINING THEM | CERMOL S.A. (CH) | 2001-09-13 | — | — | WO | disclosed |
| EP-1132381-A1 | Ester derivatives of dimethylpropionic acid and pharmaceutical compositions containing them | CERMOL S.A. (CH) | 2001-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | PYGM, CPT1B, GYS1 | NPBWR1 2640/4885MAPT 3113/4885RAB9A 3748/4885 |
| US-20140011782-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | PYGM, CPT1B, GYS1 | NPBWR1 2640/4885MAPT 3113/4885RAB9A 3748/4885 |
| US-20140018320-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | NR0B1, NR0B2, NR3C1 | NPBWR1 146/4885MAPT 4858/4885RAB9A 4325/4885 |
| US-20090075938-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | NR0B1, NR0B2, NR3C1 | NPBWR1 146/4885MAPT 4858/4885RAB9A 4325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.